Research & Regulatory News

TRIUMPH-4: The First Retatrutide Phase 3 to Read Out

UKPWritten and published by UK Peptides5 min readUpdated 3 cited sources

The short answer

TRIUMPH-4 (NCT05931367) is a completed Phase 3 trial of retatrutide in 445 adults with obesity or overweight and knee osteoarthritis. It had co-primary endpoints of body weight and WOMAC pain, ran 68 weeks, and reported topline on 11 December 2025 as the first successful Phase 3 in the programme.

Key facts

Registration
NCT05931367
Registered acronym
TRIUMPH-4
Phase
3, randomised, double-blind, placebo-controlled
Enrolment
445 (actual)
Randomisation
1:1:1
Treatment period
68 weeks, plus 4-week safety follow-up
Co-primary 1
Change in WOMAC pain subscale score
Co-primary 2
Percent change from baseline in body weight
Started
1 August 2023
Completed
14 November 2025
Topline announced
11 December 2025
Status
Completed

Why this trial read out first

Retatrutide's programme is named for obesity, but the first pivotal trial to report was the one in knee osteoarthritis. TRIUMPH-4 started in August 2023 and completed in November 2025; topline came on 11 December 2025, ahead of the pure obesity readouts that followed in 2026. That ordering matters for how the numbers were received. The first Phase 3 evidence anyone saw for this compound came from a population selected for joint disease, not for metabolic risk, and enrolled under criteria that excluded diabetes entirely.

Who was actually enrolled

The entry criteria are more specific than most coverage conveys, and they shape every number the trial produced. Participants needed a BMI of at least 27 kg/m2, index knee pain for more than 12 weeks before screening and on more than 15 days of the previous month, radiographic change of Kellgren-Lawrence grade 2 or 3 on a centrally read knee X-ray, and a diagnosis meeting American College of Rheumatology clinical and radiological criteria for osteoarthritis. Diabetes was an exclusion. So were steroid joint injections within 90 days, other joint injections or procedures within six months, joint disease other than osteoarthritis, weight-loss drugs within 90 days, a self-reported or documented weight change greater than 5 kg in the previous 90 days, and prior or planned bariatric surgery.

  • BMI threshold 27, not 30 (a lower bar than most obesity trials)
  • Kellgren-Lawrence grade 2 or 3: moderate structural change, centrally read
  • No pain-severity threshold at entry, only pain duration and frequency
  • Diabetes excluded, which removes the population where incretins were first studied
  • Recent weight change over 5 kg excluded, to keep the baseline stable

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The weight numbers, and why there are two sets of them

Lilly reported body weight under two estimands, and they are not interchangeable. The efficacy estimand (what happens if participants stay on randomised treatment without rescue) gave -26.4% (-29.1 kg) on the arm escalated to 9 mg, -28.7% (-32.3 kg) on the arm escalated to 12 mg, and -2.1% (-2.1 kg) on placebo. The treatment-regimen estimand, which counts what happened to everyone regardless of what they did afterwards, gave -20.0% (-22.9 kg), -23.7% (-27.2 kg) and -4.6% (-5.3 kg). The 28.7% figure that travelled in headlines is the efficacy estimand at the higher dose. Both estimands are legitimate; they answer different questions, and a comparison that mixes them is meaningless. These are dose arms in a registered trial conducted under clinical supervision, described here as facts about the trial and nothing else.

The pain result, stated properly

The WOMAC pain subscale was scored on the 0-20 Likert version, and mean baseline was 6.0 points, toward the mild end of that range. Under the efficacy estimand, the 9 mg arm fell 4.5 points (-75.8%), the 12 mg arm fell 4.4 points (-74.3%), and placebo fell 2.4 points (-40.3%). Complete resolution of index knee pain was reported in 14.1% of the 9 mg arm, 12.0% of the 12 mg arm and 4.2% of placebo. Two things in that paragraph deserve more attention than they have had. The placebo arm improved by 40% of its baseline pain, which is enormous and entirely typical of osteoarthritis pain trials. And the higher dose, which produced more weight loss, did not produce more pain relief.

Tolerability, and what it costs to go from 9 mg to 12 mg

Discontinuation due to adverse events was 12.2% on the 9 mg arm, 18.2% on the 12 mg arm and 4.0% on placebo. The most common adverse events were gastrointestinal: nausea in 38.1-43.2% across the active arms, diarrhoea in 33.1-34.7%, constipation in 21.8-25.0% and vomiting in 20.4-20.9%. Put the efficacy and tolerability together and the higher dose bought 2.3 percentage points more weight loss and six percentage points more discontinuation, while measuring slightly worse on both pain endpoints. That is the kind of arithmetic that decides which dose is filed, and it is invisible if you only read the headline number.

What TRIUMPH-4 does not establish

It does not show that retatrutide treats osteoarthritis, and nothing here should be read that way. It shows that in a trial of 445 people meeting specific radiographic and symptomatic criteria, a randomised comparison moved two pre-specified endpoints over 68 weeks. The structural question (whether cartilage loss slows) was not a primary endpoint and the trial was not designed to answer it. WOMAC is a patient-reported symptom instrument; it records what people say they feel, which is the outcome that matters to them, but it is not a measure of joint structure.

Quick reference

Endpoint at week 68Retatrutide 9 mg armRetatrutide 12 mg armPlacebo
Body weight, efficacy estimand-26.4%-28.7%-2.1%
Body weight, treatment-regimen-20.0%-23.7%-4.6%
WOMAC pain, points from 6.0-4.5 (-75.8%)-4.4 (-74.3%)-2.4 (-40.3%)
Complete knee pain resolution14.1%12.0%4.2%
Discontinued for adverse events12.2%18.2%4.0%

Frequently asked questions

Is TRIUMPH-4 published?

Not as a full peer-reviewed paper at the time of writing. The results described here come from the sponsor's topline release of 11 December 2025 and its published medical-information summary. Lilly stated that detailed results would be presented at a medical meeting and submitted to a peer-reviewed journal. Sponsor summaries and peer-reviewed papers are different evidentiary objects, and the distinction is worth holding on to.

Why did the 12 mg arm do worse on pain?

Nobody knows, and the trial was not designed to compare the two active arms against each other. The differences (4.4 versus 4.5 points, 12.0% versus 14.1%) are small, unpowered, and consistent with chance. They are also consistent with a pain endpoint that saturates: from a baseline of 6.0 points, both arms had already removed about three-quarters of the measurable pain.

Does the placebo result mean the drug did little?

No, but it means the drug did less than the raw active-arm number suggests. The comparison that carries information is the difference between arms, not the change within one. On WOMAC pain that difference is roughly 2.0-2.1 points, not 4.5. On complete pain resolution it is about ten percentage points. Both are meaningful; neither is what a 75.8% figure sounds like on its own.

Can retatrutide be used for knee pain?

No. Retatrutide is not licensed anywhere for any indication. It is an investigational compound, and material sold for laboratory research is not a medicine and is not an alternative to one. Anyone with joint pain should be talking to a clinician about licensed options.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.